Consensus Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE 00:00:00 18/09/2026 +04			5-day change	1st Jan Change
2.880 ^USD	+6.67%		-3.68%	+4.73%

08-19	BMO Capital Initiates Perspective Therapeutics at Outperform	MT
08-14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT

Evolution of the Average Target: Perspective Therapeutics, Inc.

Evolution of the Target Price: Perspective Therapeutics, Inc.

Changes in Analyst Recommendations: Perspective Therapeutics, Inc.

94a473b535faddb5d4474e89ea6.WrKGs_-MeSTflOAwrzGWfkGPPIgRhjgns1RHaYExB-E.Fv3cy77fKGiL5NFo5wekLQLtTNIi1XsW3iYQKPdfUJAcyM7wnvQQYpns0A~0173067d71c8fa0fdaf56adefd67c254

Analysts' recommendations: Perspective Therapeutics, Inc.

08-19	BMO Capital Initiates Perspective Therapeutics at Outperform	MT
08-14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT
08-11	Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says	MT
03-18	UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating	MT
03-18	B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating	MT
03-17	RBC Cuts Price Target on Perspective Therapeutics to $14 From $18, Keeps Outperform, Speculative Risk	MT
02-19	Piper Sandler Initiates Coverage on Perspective Therapeutics With Overweight Rating	MT
11-18	B. Riley Adjusts Price Target on Perspective Therapeutics to $11 From $12, Maintains Buy Rating	MT
10/10/25	BTIG Research Initiates Coverage on Perspective Therapeutics With Buy Rating, $14 Price Target	MT
23/06/25	B. Riley Raises Price Target on Perspective Therapeutics to $12 From $9, Keeps Buy Rating	MT
03/06/25	RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk	MT
14/05/25	Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating	MT
13/05/25	Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating	MT
07/04/25	Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating	MT
27/03/25	RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk	MT
13/03/25	HC Wainwright Initiates Coverage on Perspective Therapeutics With Buy Rating, $10 Price Target	MT
10/03/25	Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target	MT
26/11/24	B. Riley Securities Adjusts Price Target on Perspective Therapeutics to $9 From $17, Keeps Buy Rating	MT
25/11/24	BofA Securities Downgrades Perspective Therapeutics to Neutral From Buy, Price Target is $6	MT
25/11/24	RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk	MT
13/11/24	RBC Trims Price Target on Perspective Therapeutics to $25 From $27, Keeps Outperform, Speculative Risk	MT
24/10/24	UBS Initiates Perspective Therapeutics at Buy With $20 Price Target	MT
11/10/24	Top Midday Decliners	MT
11/10/24	Wedbush Adjusts Price Target on Perspective Therapeutics to $20 From $25, Maintains Outperform Rating	MT
01/10/24	Wedbush Initiates Perspective Therapeutics at Outperform With $25 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PERSPECTIVE THERAPEUTICS, INC.					+355.03%
	LONZA GROUP AG					+27.82%
	IQVIA HOLDINGS INC.					+3.39%
	REVOLUTION MEDICINES, INC.					+28.22%
	BEONE MEDICINES AG					+24.34%
	CELLTRION, INC.					+51.37%
	MEDPACE HOLDINGS, INC.					-5.61%
	ASCENDIS PHARMA A/S					+26.23%
	EUROFINS SCIENTIFIC SE					-3.29%
	ICON PUBLIC LIMITED COMPANY					+6.68%
	Average					+51.42%
	Weighted average by Cap.					+21.33%